227 related articles for article (PubMed ID: 28923385)
1. Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.
Hsieh HY; Chuang HC; Shen FH; Detroja K; Hsin LW; Chen CS
Eur J Med Chem; 2017 Nov; 140():42-51. PubMed ID: 28923385
[TBL] [Abstract][Full Text] [Related]
2. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
3. Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Chao MW; Chu PC; Chuang HC; Shen FH; Chou CC; Hsu EC; Himmel LE; Huang HL; Tu HJ; Kulp SK; Teng CM; Chen CS
Oncotarget; 2016 Jan; 7(2):1796-807. PubMed ID: 26625202
[TBL] [Abstract][Full Text] [Related]
4. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.
Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
8. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy.
Patel HK; Siklos MI; Abdelkarim H; Mendonca EL; Vaidya A; Petukhov PA; Thatcher GR
ChemMedChem; 2014 Mar; 9(3):602-13. PubMed ID: 23956109
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Liu R; Wang J; Tang W; Fang H
Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Opportunities of Targeting Histone Deacetylase Isoforms to Eradicate Cancer Stem Cells.
Lin PC; Hsieh HY; Chu PC; Chen CS
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30004423
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
Seidel C; Schnekenburger M; Zwergel C; Gaascht F; Mai A; Dicato M; Kirsch G; Valente S; Diederich M
Bioorg Med Chem Lett; 2014 Aug; 24(16):3797-801. PubMed ID: 25042254
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH
Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381
[TBL] [Abstract][Full Text] [Related]
14. Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors.
Wünsch M; Senger J; Schultheisz P; Schwarzbich S; Schmidtkunz K; Michalek C; Klaß M; Goskowitz S; Borchert P; Praetorius L; Sippl W; Jung M; Sewald N
ChemMedChem; 2017 Dec; 12(24):2044-2053. PubMed ID: 29120081
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.
Zhou Y; Dun Y; Fu H; Wang L; Pan X; Yang X; Fang H
Chem Biol Drug Des; 2017 Nov; 90(5):936-942. PubMed ID: 28489276
[TBL] [Abstract][Full Text] [Related]
16. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents.
Cheng J; Qin J; Guo S; Qiu H; Zhong Y
Bioorg Med Chem Lett; 2014 Oct; 24(19):4768-4772. PubMed ID: 25182565
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification.
Liu C; Liu L; Shan J; Shen J; Xu Y; Zhang Q; Yang Z; Wu L; Xia F; Bie P; Cui Y; Zhang X; Bian X; Qian C
Cancer Lett; 2013 Oct; 339(1):60-9. PubMed ID: 23879963
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of histone deacetylase as antitumor agents: A critical review.
Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
[TBL] [Abstract][Full Text] [Related]
20. Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
Gaisina IN; Tueckmantel W; Ugolkov A; Shen S; Hoffen J; Dubrovskyi O; Mazar A; Schoon RA; Billadeau D; Kozikowski AP
ChemMedChem; 2016 Jan; 11(1):81-92. PubMed ID: 26592932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]